Pharma & Biotech

Cancer therapy

Advances in screening, targeted and immune therapies, big data and computational methods are transforming how we diagnose, treat and stratify cancer. Despite this progress, we recognize the increasing complexity of cancer research. Our extensive cancer portfolio includes kits, reagents and instruments for a range of areas:

  • Automated sample preparation
  • Liquid biopsy analysis
  • Analysis of gene variant or gene expression alterations
  • miRNA biomarker discovery
  • Cancer microbiome studies
  • Oncohematology research
Multiple Cancer Catalogued Panels

Liquid biopsy is a minimally invasive alternative to surgical biopsies and enables the detection of highly specific and sensitive biomarkers that can be used in routine cancer screening, monitoring of tumor progression, to predict response or resistance to cancer therapies and minimal residual disease monitoring.

Liquid biopsy can be used to detect and analyze cancer-derived components including cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) and exosome from blood or biofluid samples.

Challenges of liquid biopsy include greater sensitivity required to detect low levels of nucleic acids against a high background and the degradation of precious samples.

Our PAXgene technology for gold-standard sample collection and stabilization, trusted manual and automated sample preparation offer solutions for all liquid biopsy analytes, and integrated NGS or  digital PCR-based workflows, to help you overcome these.

Liquid Biopsy biofluid
cfDNA workflow solutions
Get an overview of the products that can help you develop an easy and reliable cfDNA workflow
Three simple steps to isolate DNA and RNA

The power of two – EZ2 Connect and QIAcuity

The successful biomarker profiling from liquid biopsies (cfDNA) and FFPE samples is a challenging endeavor with target mutations present in low quantities against a complex background of other components.

That's why we bring you the power of two. For successful biomarker profiling from liquid biopsies and FFPE samples, you can combine the fully automated and convenient high-volume processing of samples on the EZ2 Connect with fast and sensitive ultra-low mutation detection on the QIAcuity digital PCR system. 

Would you like a demo?
Automation is a huge decision. How about trying out our instruments for free before you decide? Just fill the request form to qualify for a no-obligation demo.

Digital PCR is an established method for the fast and reliable identification of significant cancer-related mutations. It is now routinely used for:

  • absolute allele quantification
  • rare mutation detection
  • identification of targets in complex mixtures
  • analysis of copy number variations
  • DNA methylation
  • gene rearrangements
A woman in a lab coat in a lab looking at a tablet

Digital PCR can be harnessed to identify residual cancer below current detection levels, detect new mutations and duplications in cancer and monitor rare drug-resistance mutations. The QIAcuity Digital PCR System allows for increased sensitivity in the detection and absolute quantification of rare events/sequence variants because target quantification is independent of the number of amplification cycles.

Copy number variations (CNVs) of specific genes are involved in the development and progression of many cancers. Therefore, the quantitative analyses of CNVs at disease-associated loci provide insights into molecular mechanisms of diseases and facilitates the discovery of novel biomarkers. The QIAcuity Digital PCR System enables accurate detection of copy numbers in the genome, making itan indispensable tool for the subsequent analysis of copy number alterations underlying disease progression.

To help you take advantage of this highly precise technology, we offer a complete solution for digital PCR-based mutation detection and copy number variation studies.

dPCR Q and A webinar

Sensitive mutation analysis by dPCR Q&As

Watch the webinar on-demand to hear our panel of experts answer the most pressing questions and share their tips on quantifying rare targets of interest in cfDNA and FFPE samples using digital PCR.

You can look forward to a focused discussion on the challenges you face every day in the lab when working with complex samples.

dPCR Services
Check out our services designed specifically for dPCR-based mutation detection and copy number variation studies.
QIAGEN production

Customized NGS panels 

Are you looking for a partner to help you develop customized NGS panels for commercialization? We have the R&D expertise to develop NGS panels in a convenient kit-based format for your specific requirements and timeframe. Using our experience in CDx development, we can also support you through the process of acquiring the necessary regulatory approvals for global commercialization.

For more information, please get in touch with us.

NGS has revolutionized genomic profiling of cancers for precision oncology. Discover our consolidated workflow for DNA and RNA library preparation using total nucleic acids as the input. This means that it is no longer necessary to divide precious samples, thereby decreasing the amount of starting material that is required and reducing lengthy turnaround times. This enables you to assess DNA and RNA alterations, tumor mutational burden (TMB) and microsatellite instability (MSI) in a single workflow.
Multimodal Cancer Genomics Profiling Services
QIAGEN Genomic Services provides a complete end–to-end  service  for multimodal analysis from sample preparation to data analysis.
Explore our complete NGS portfolio
Check out our complete portfolio for NGS-based cancer applications

It is now understood that the microbiome can affect tumor initiation, serve as a predictor of disease progression and survival and determine the response to cancer therapies. Modulation of the microbiome can enhance the efficacy of cancer therapies, including immunotherapies and decrease their toxicity.  With the advent of NGS and high-throughput sequencing, we can now study in detail the link between the microbiome and cancer.  As such, distinct dysbiotic microbial signatures associated with different tumor states are increasingly recognized using high-throughput sequencing techniques.

We've developed dedicated products that help to unravel the role of the host-associated microbial communities in cancer from DNA/RNA isolation kits to microbial transcriptome and genome profiling and data analysis.

Microbiome icon
QDI, Indian male, sitting at desk pointing to computer screen

From data analysis to databases, from gene expression to genome assembly, from interpretation to integration – QIAGEN Digital Insights has the breadth and quality of bioinformatics tools you need to drive meaningful insights and fuel new cancer discoveries.

Oncology Applications: